Investigating the role of tau in dementia using patient-derived cell models: distinct mechanisms or common endpoint?
Status / Stage
CompletedDates
1 April 2017 -31 March 2021
Duration (calculated)
03 years 11 monthsFunder(s)
Alzheimer's Research UKFunding Amount
£417,762.30Funder/Grant study page
Alzheimer's Research UKContracted Centre
University College LondonPrincipal Investigator
Dr Selina WrayPI Contact
selina.wray@ucl.ac.ukWHO Catergories
Models of DiseaseUnderstanding risk factors
Understanding Underlying Disease
Disease Type
Dementia (Unspecified)CPEC Review Info
| Reference ID | 217 |
|---|---|
| Researcher | Reside Team |
| Published | 12/06/2023 |
Data
| Status / Stage | Completed |
|---|---|
| Start Date | 20170401 |
| End Date | 20210331 |
| Duration (calculated) | 03 years 11 months |
| Funder/Grant study page | Alzheimer's Research UK |
| Contracted Centre | University College London |
| Funding Amount | £417,762.30 |
Aims
The findings from this Fellowship can feed directly into early drug discovery programmes that take these biological processes to search for experimental drugs that can block them. Anything that could alter tau’s toxic effects would have the potential to offer renewed hope to hundreds of thousands of people with dementia across the country.